ReviewCureus2022
A Review on the Use of the HPV Vaccine in the Prevention of Cervical Cancer.
Review in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Acceptance of HPV Vaccination: A Systematic Review of Knowledge, Attitudes and Barriers Among Healthcare Practitioners in Low- and Middle-Income Countries.BioMed research international · 2026Pooled it
- Perceptions of HPV-Linked Oropharyngeal Cancer Risk Messages Among a Sample of Young Adult Men in the US: A Pilot Study.American journal of men's healthTrial
- Investigation of Youth Attitudes and Opinions Regarding HPV: A Systematic Review.Healthcare (Basel, Switzerland) · 2026Review
- Cancer Vaccines: Mechanisms, Clinical Applications, Challenges, and Future Directions in Precision Medicine.Current cancer drug targets · 2026Review
- An investigation of HPV vaccination willingness and influential factors among college students in Beijing based on the BeSD framework and evaluation of momentary intervention effect.Human vaccines & immunotherapeutics · 2025Article
- Preventive insights and practices of female health professionals regarding cervical cell dysplasia: a cross-sectional study in Egypt.BMC public health · 2025Article
- Papillomavirus Vaccination Programs and Knowledge Gaps as Barriers to Implementation: A Systematic Review.Vaccines · 2025Review
- Article
- Molecular analysis of HPV16 and HPV18 oncogenes in oral squamous cell carcinoma: Structural, transcriptomic andOncology letters · 2025Article
- Spatiotemporal dynamics and prevention strategies of cervical cancer incidence in Addis Ababa, Ethiopia: an ecological study.BMJ open · 2025Article
- The role of pioneering transcription factors, chromatin accessibility and epigenetic reprogramming in oncogenic viruses.Frontiers in microbiology · 2025Review
- Unraveling the triad of immunotherapy, tumor microenvironment, and skeletal muscle biomechanics in oncology.Frontiers in immunology · 2025Review
- Sociodemographic and clinical factors associated with delayed diagnosis of cervical cancer: a cross-sectional study, Brazil, 2016-2020.Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil · 2025Article
- Curcumin, EGCG and apigenin in cervical cancer: mechanistic insights and therapeutic potential.Frontiers in pharmacology · 2025Review
- Organizational barriers in HPV vaccination uptake: A cross-sectional study among health sciences students.PloS one · 2025Article
- Perceptions and Barriers to Human Papillomavirus Vaccination and Cervical Cancer Screenings: A Survey Study of Underserved Populations in North Texas.Public health challenges · 2024Article
- Article
- Women's knowledge, attitude, and practice regarding cervical precancerous lesions: a cross-sectional study in Beijing, China.Frontiers in public health · 2024Article
- Article
- Nurses and doctors 's awareness and knowledge towards treatment and care of cervical cancer patients: a cross-sectional study.BMC nursing · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The main risk factor for invasive cervical carcinoma is persistent infection by the high-risk human papillomavirus (HPV). HPV is the most prevalent sexually transmitted infection (STI) and has been linked to 15 different cancers. Cervical cancer is one of the most frequent cancers among women, particularly in resource-limited countries. Cervical cancer is an HPV disease with the highest worldwide burden in resource-limited nations. With improved medical care and nationwide screening programmes, the mortality rate from cervical cancer has decreased in the past 40 years. Many developing nations have been shown to have inadequate knowledge and health-seeking practices, making proper awareness and immunisation programmes necessary. The best strategy to reduce the incidence of cervical cancer is through the administration of HPV vaccines along with routine cervical screening. The HPV vaccine is crucial for public health. Vaccinations against all HPV subtypes, namely, bivalent, quadrivalent, and nonavalent, are available. Financial issues are the main barrier to HPV vaccination. The framework for behavioural and social drivers of vaccination, which includes practical concerns, motivation, social processes, thoughts, and feelings, is widely used to uncover important aspects linked with HPV vaccination. The burden of cervical cancer due to HPV and the advantages of HPV vaccination are summarised in this review article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.